[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"c-section\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:c-section":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100638747","influence-of-probiotics-on-early-gut-microbial-colonization-100638747",false,"NCT07608341","Influence of Probiotics on Early Gut Microbial Colonization","Influence of Probiotics on Early Gut Microbial Colonization, Safety and Tolerability in Infants Born by Caesarean Section","STORKIE","Inclusion Criteria:\n\nInfant born by planned C-section or vaginal born infant\n\nGestational age at birth ≥ 37±0 weeks to \\\u003C41 ±0 weeks\n\nInfant Apgar score 7-10, (5 minutes after birth)\n\nIntention to breastfeed the infant\n\nParents\u002Flegal guardians are \\>18 years\n\nParents\u002Flegal guardians have readiness and the opportunity to fill out a study diary, questionnaires and agree to collect biological samples\n\nParents\u002Flegal guardians with ability to understand and comply with the requirements of the study, as judged by the Investigator\n\nParents\u002Flegal guardians are willing and able to give written informed consent for their and their infants participation in the study\n\nExclusion Criteria:\n\n\\>72 hours after birth when collecting the first faecal sample and given the first drops of study product\n\nInfants classified as small for gestational age (SGA), defined as birth weight \\\u003C -2 standard deviations (SD) for gestational age and sex according to national reference standards.\n\nInfants with birth of congenital malformations or anomalies\n\nInfants not able to feed adequately by oral means at the time of screening (i.e., requiring tube feeding)\n\nInfants requiring care in neonatal unit\n\nDisruption of amniotic membranes for \\>24 hours\n\nInfants consuming probiotics, including in infant formula\n\nMothers use of antibiotics during the last 14 days of pregnancy prior to delivery\n\nParticipation in other clinical studies\n\nAny other disease, condition, or circumstance that, in the investigator's opinion, may compromise the participant's safety, adherence to the protocol, or the interpretation of study results",true,"ALL","0 Days","3 Days",{"count":22,"type":23},150,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to learn whether daily probiotic drops plus vitamin D3 can improve early gut microbiome colonization in healthy infants born by C-section. It will also assess safety and tolerability.\n\nAn intervention with probiotics + vitamin D3 will be compared to placebo + vitamin D3 in a double-blind, randomized design, and include an open-label vaginal-born reference group.\n\nParticipants will receive study drops daily for 8 weeks and provide stool samples at multiple time points and complete questionnaires\u002Fdiaries. After the intervention period, there is an optional follow-up period for up to 3 years.",[29],"C-Section",[31,32,33,34],"microbiome","c-section","probiotic","gut microbiome","NOT_YET_RECRUITING","2026-05-19",{"date":38,"type":39},"2026-05-27","ACTUAL",{"date":41,"type":23},"2026-08-01",{"date":43,"type":23},"2030-08-01",{"name":45,"class":46},"BioGaia AB","INDUSTRY",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100478064","early-phase-1-modification-of-the-early-life-respiratory-microbiome-through-vaginal-seeding-100478064","NCT05505110","MOdification Of THe Early-Life Respiratory Microbiome Through Vaginal SEEDing","MOTHER SEED","Inclusion Criteria:\n\nFor the mother:\n\n* Female 18-40 years of age who is in good general health, is fully able to provide consent to participate in the study, anticipates being available for the duration of the study, and is willing to comply with all study procedures\n* Singleton pregnancy\n* Completed ≧3 prenatal care visits at Vanderbilt University Medical Center (any facility)\n* Having rectovaginal swabs collected at ≧36 weeks of gestation to screen for Group B Streptococcus (GBS) as part of prenatal screening tests\n* Having a scheduled (planned or non-emergency) C-section at Vanderbilt University Medical Center (main campus only)\n* No intent to relocate outside the middle Tennessee region within 12 months of recruitment\n\nFor the child:\n\n* Estimated gestational age ≧37 weeks\n* Birth weight ≧2,500 grams\n\nExclusion Criteria:\n\nFor the mother:\n\n* Past medical history of any of the following:\n\n  * Previous child with GBS infection or prior positive GBS testing\n  * Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection\n  * Genital herpes simplex virus (HSV) infection, genital herpetic lesions, or prior positive genital HSV testing\n  * Genital human papilloma virus (HPV) infection, genital HPV lesions, or prior positive genital HPV testing\n  * Diabetes type I or type II\n* Laboratory evidence during the current pregnancy of any of the following:\n\n  * GBS bacteriuria in urine samples collected at any time (performed as standard of care)\n  * GBS colonization in rectovaginal swabs collected at ≧36 weeks of gestation (performed as standard of care)\n  * Chlamydia, trichomoniasis, or gonorrhea in urine samples collected at ≧36 weeks of gestation (performed as part of the screening procedures for this study)\n  * Hepatitis B, hepatitis C, HIV, or syphilis in blood samples collected at ≧36 weeks of gestation (performed as part of the screening procedures for this study)\n* Uncontrolled gestational diabetes\n* Any serious obstetric disease (e.g., preeclampsia with severe features, placental abruption or severe bleeding, or thromboembolic disease) as deemed by the PI or co-investigators\n* Prior abnormal Pap smear\n* C-section scheduled for a genitourinary infection that would have interfered with vaginal delivery (e.g., genital herpetic lesions)\n* Lack of available prenatal screening tests\n* Use of systemic (i.e., oral, intramuscular, or intravenous) antibiotics in the 4 weeks prior to delivery (except for those being administered as part of the C-section)\n* Use of systemic (i.e., oral, intramuscular, or intravenous) immunosuppressive, biologic, or chemotherapeutic agents in the 3 months prior to delivery (except for systemic immunosuppressive agents not being used for their immunosuppressive effects \\[e.g., prenatal intramuscular beclomethasone for fetal lung maturation\\])\n* Fever (≧100.4°F \\[38°C\\]) in the 72 hours prior to delivery\n* Symptoms (e.g., dysuria, pruritus, or discharge) suggestive of a genitourinary infection (e.g., bacterial vaginosis, vaginal yeast infection, chorioamnionitis, or urinary tract infection) on the day of delivery\n* Symptoms (e.g., pain, tenderness, tingling, burning, itching, or swollen lymph nodes) suggestive of genital HSV infection on the day of delivery\n* Other symptoms (e.g., new-onset rhinorrhea, sore throat, cough, body aches, chills, nausea, vomiting, or diarrhea) suggestive of an acute infectious disease on the day of delivery\n* Physical exam findings (e.g., fever \\[≧100.4°F (38°C)\\] or vesicles, warts, or ulcers in the genital, perineal, or anal region) suggestive of a genitourinary infection on the day of delivery (performed as part of the screening procedures for this study if not performed as standard of care)\n* Maternal vaginal pH\\>4.5 on the day of delivery (performed as part of the screening procedures for this study)\n* Need for a switch from a scheduled C-section to an emergency C-section\n* Prelabor prolonged rupture of membranes (i.e., ≧18 hours prior to delivery)\n* Pregnancy as the result of an assisted reproductive technology or surrogacy\n* Participation in another clinical trial that involves an intervention that could impact the quality or interpretation of the study data as deemed by the PI or co-investigators\n* Other past or current medical problems that could compromise the safety of participants, interfere with their ability to comply with study requirements, or impact the quality or interpretation of the study data as deemed by the PI or co-investigators\n\nFor the child:\n\n* Need for neonatal measures outside routine clinical care (i.e., drying, tactile stimulation, bulb syringe or catheter suction of nose and mouth, or temperature maintenance) in the delivery room\n* Transfer to the neonatal intensive care unit immediately after delivery\n* Thick particulate meconium noted during delivery\n* Physical exam findings (e.g., tachypnea, nasal flaring, retractions, cyanosis, or grunting) suggestive of neonatal acute respiratory distress immediately after delivery (performed as part of the screening procedures for this study)\n* Prenatal diagnosis of a serious genetic, respiratory, cardiovascular, or neurological disease\n* Prenatal diagnosis of intrauterine growth restriction\n* Prenatal diagnosis of a major congenital anomaly (e.g., cleft lip or palate, cystic hygroma, or giant omphalocele)\n* Participation in another clinical trial that involves an intervention that could impact the quality or interpretation of the study data as deemed by the PI or co-investigators\n* Other past or current medical problems that could compromise the safety of participants, interfere with their ability to comply with study requirements, or impact the quality or interpretation of the study data as deemed by the PI or co-investigators","FEMALE","18 Years","40 Years",{"count":59,"type":23},20,[61],"EARLY_PHASE1","This is a single-center, parallel-arm, blind, sham-controlled, feasibility randomized controlled trial (RCT) to be conducted in healthy cesarean-born children. Eligible children will be randomized 1:1 to have their nose swabbed with either maternal vaginal secretions or a sterile swab (intervention vs. control group, respectively). The main hypothesis is that conducting an RCT assessing the utility of vaginal seeding in modifying the early-life upper respiratory tract (URT) microbiome of children born by cesarean section (C-section) is feasible and that the intervention is safe.",[64,65,66,67],"C-section","Vaginal Seeding","Respiratory","Microbiome",[64,69,66,67],"Vaginal seeding","RECRUITING","2025-11-06",{"date":73,"type":39},"2025-11-10",{"date":75,"type":39},"2022-11-09",{"date":77,"type":23},"2028-08-10",{"name":79,"class":80},"Vanderbilt University Medical Center","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":17,"sex":55,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100563941","effect-of-kinesio-taping-on-post-c-section-pain-and-comfort-100563941","NCT06622707","EFFECT OF KINESIO TAPING ON POST-C-SECTION PAIN AND COMFORT","Inclusion Criteria:\n\n* patients having C-section delivery in the 37th and 40th gestational weeks,\n* patients giving birth to just a baby,\n* patients with no chronic disease (such as allergy, diabetes, or hypertension),\n* patients having no problems with communication,\n* patients with no dermatological disease.\n\nExclusion Criteria:\n\n* patients whose babies are in the neonatal intensive care unit,\n* patients with deep vein thrombosis, open wounds, or skin irritation,\n* patients who did not want to participate in the study,","19 Years","45 Years",{"count":91,"type":23},60,[26],"Kinesio taping gently stretches the skin and creates a gap between the dermis and fascia, increasing lymphatic and vascular flow and reducing pain without restricting movement. It is used to provide rehabilitation after surgical operations. This study will be conducted to determine the effect of kinesio taping on the mother\\'s pain and comfort after cesarean section. It is planned to include 60 women who gave birth by cesarean section in the obstetrics and gynecology department at Şırnak State Hospital. Research data will be collected with the visual analog scale and postpartum comfort scale. If the data shows normal distribution, Unrelated Samples t Test, Related Samples t Test and Repeated Measures ANOVA (Repeated Measures) tests will be used.",[29],[96,97,98],"Kinesio Taping","Pain","Postpartum Comfort","2024-09-29",{"date":101,"type":39},"2024-10-02",{"date":103,"type":23},"2024-11-05",{"date":105,"type":23},"2025-03-02",{"name":107,"class":80},"Şırnak Üniversitesi"]